Successful Treatment with Entecavir for Reactivation of Hepatitis B Virus Following Systemic Chemotherapy in a Hepatitis B Surface Antigen-negative Patient with Colorectal Cancer
-
- Okagawa Yutaka
- Department of Internal Medicine and Gastroenterology, Date Red Cross Hospital, Japan Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Takada Kohichi
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Hisai Hiroyuki
- Department of Internal Medicine and Gastroenterology, Date Red Cross Hospital, Japan
-
- Koshiba Yutaka
- Department of Internal Medicine and Gastroenterology, Date Red Cross Hospital, Japan
-
- Wada Hironori
- Department of Internal Medicine and Gastroenterology, Date Red Cross Hospital, Japan
-
- Miyazaki Etsu
- Department of Internal Medicine and Gastroenterology, Date Red Cross Hospital, Japan
-
- Kanari Yusuke
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Kawano Yutaka
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Iyama Satoshi
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Hayashi Tsuyoshi
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Sato Tsutomu
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Sato Yasushi
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Miyanishi Koji
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Kobune Masayoshi
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Takimoto Rishu
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
-
- Kato Junji
- Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Japan
この論文をさがす
抄録
Reactivation of hepatitis B virus (HBV) has recently been reported as a fatal complication in patients undergoing cytotoxic chemotherapy. We herein describe a case of reactivation in a 76-year-old man who had undergone pelvic exenteration for colorectal cancer (CRC). He was treated with a modified FOLFOX6 chemotherapy regimen after the operation. Thirteen months later, his laboratory data showed severe liver dysfunction. His hepatitis B surface antigen (HBsAg) test was positive, and his HBV-DNA level was elevated. We diagnosed the patient with HBV reactivation as his HBsAg test was negative before starting chemotherapy. His liver dysfunction improved after administration of entecavir. This is the first report describing HBV reactivation following chemotherapy for an HBsAg-negative CRC patient.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 53 (16), 1759-1762, 2014
一般社団法人 日本内科学会
